Study of AB521 for kidney cancer and other solid tumors
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This early-stage trial tests AB521, alone and in combination with other medicines, in people with advanced solid tumors—especially clear cell kidney cancer. It aims to find a safe dose and see whether the treatment could help shrink tumors or control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have at least one measurable tumor spot on scans (the trial can track it).
- You are well enough to do daily activities (ECOG score 0–1).
- Your kidney filtering function is good (creatinine clearance at least 40 mL/min).
- For dose-expansion, you must have confirmed clear cell kidney cancer (ccRCC).
- You cannot have had major surgery or significant injury within the last 28 days.
- You must not have had certain recent medicines or treatments (including prior HIF-2α inhibitor for expansion, and specific prior treatments for combo groups).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This study tests whether adding a drug called cabozantinib to standard nivolumab treatment helps fight kidney cancer that has spread to bone. It aims to understand how the bone environment changes during treatment.
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
This study tests a new combination of medications (casdatifan and zimberelimab) given before surgery to remove kidney tumors in people with clear cell renal cell carcinoma (ccRCC). The goal is to see if this approach can help shrink the tumor or improve outcomes.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.